Opinion|Videos|March 11, 2024
IMBrave-050 Study Overview
Dr Shroff breaks down the combination of atezolizumab and bevacizumab as outlined by the IMBrave-050 study.
Advertisement
Episodes in this series
Advertisement
Related to this article
In HARMONi-GI1, ivonescimab plus chemotherapy extended survival over durvalumab plus chemotherapy in untreated advanced biliary tract cancer.
Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.
Arcotatug tavatecan improved PFS and OS vs physician’s choice in previously treated, CLDN18.2-positive advanced gastric and GEJ cancer.
Overall survival benefit of daraxonrasib vs chemotherapy extends across RAS genotypes, chemotherapy regimens, and prior treatment settings.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
The FDA granted fast track designation to MC001 for pancreatic cancer.
Advertisement
Advertisement
Trending on OncLive
1
Divarasib Improves Survival and Paves Way for New SOC in Pretreated KRAS G12C–Mutated NSCLC
2
Ivonescimab Plus Chemotherapy Represents a New SOC in First-Line Biliary Tract Cancer
3
SAFFRON Data Reveal New Global SOC in EGFR+ NSCLC With MET Overexpression and/or Amplification After Osimertinib
4
Tovecimig Plus Paclitaxel Improves ORR vs Paclitaxel Alone in Biliary Tract Cancer
5